GlassScriptPhysician profile
Mina Kalfas
NPI 1508808361
$2,303.75
in general payments reported to CMS, 2019-2025
23 companies · $684 in 2025
The $684 reported for 2025 was more than what 86% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $12.91 · 2021: $225 · 2022: $366 · 2023: $308 · 2024: $399 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $461.47 | 2019-2025 | Vivitrol, Vivitrol |
| Abbvie INC. | $349.56 | 2021-2025 | |
| Indivior INC. | $308.24 | 2019-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $271.99 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $198.29 | 2022-2025 | Fanapt, Hetlioz |
| Braeburn INC. | $192.56 | 2023-2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $64.76 | 2022 | |
| Axsome Therapeutics, INC. | $60.75 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $57.36 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $52.66 | 2021-2023 | Rexulti |
| Uswm, LLC | $51.68 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.71 | 2019 | |
| Mdd US Operations, LLC | $27.96 | 2019-2020 | |
| Astellas Pharma US INC | $27.71 | 2019 | |
| Amgen INC. | $27.03 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.21 | 2019 | |
| Pfizer INC. | $14.71 | 2019 | |
| Abbott Laboratories | $14.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.29 | 2022 | |
| Lilly USA, LLC | $11.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Kalfas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.